Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

ESMO Guidelines Committee

doi:10.1016/j.annonc.2021.02.014

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

ESMO Guidelines Committee

Research output: Contribution to journal › Letter › peer-review

313 Scopus citations

Original language	English
Pages (from-to)	801-805
Number of pages	5
Journal	Annals of Oncology
Volume	32
Issue number	6
DOIs	https://doi.org/10.1016/j.annonc.2021.02.014
State	Published - Jun 2021

Access to Document

10.1016/j.annonc.2021.02.014

Cite this

@article{3f05eedfb0e040498beffb130cb95d08,

title = "Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines",

author = "{ESMO Guidelines Committee} and A. Vogel and E. Martinelli and A. Cervantes and I. Chau and B. Daniele and Llovet, {J. M.} and T. Meyer and Nault, {J. C.} and U. Neumann and J. Ricke and B. Sangro and P. Schirmacher and C. Verslype and Zech, {C. J.} and D. Arnold",

note = "Funding Information: The ESMO Guidelines Committee thank the authors of the full ESMO Clinical Practice Guideline who drafted and reviewed this eUpdate before it was approved by the ESMO Guidelines Committee: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. M. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold and E. Martinelli. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO. Funding Information: AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO.",

year = "2021",

month = jun,

doi = "10.1016/j.annonc.2021.02.014",

language = "English",

volume = "32",

pages = "801--805",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

AU - ESMO Guidelines Committee

AU - Vogel, A.

AU - Martinelli, E.

AU - Cervantes, A.

AU - Chau, I.

AU - Daniele, B.

AU - Llovet, J. M.

AU - Meyer, T.

AU - Nault, J. C.

AU - Neumann, U.

AU - Ricke, J.

AU - Sangro, B.

AU - Schirmacher, P.

AU - Verslype, C.

AU - Zech, C. J.

AU - Arnold, D.

N1 - Funding Information: The ESMO Guidelines Committee thank the authors of the full ESMO Clinical Practice Guideline who drafted and reviewed this eUpdate before it was approved by the ESMO Guidelines Committee: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. M. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold and E. Martinelli. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO. Funding Information: AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85104668795&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.02.014

DO - 10.1016/j.annonc.2021.02.014

M3 - Letter

C2 - 33716105

AN - SCOPUS:85104668795

SN - 0923-7534

VL - 32

SP - 801

EP - 805

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -